Soleno Therapeutics (SLNO) Equity Ratio (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Equity Ratio data on file, last reported at 0.81 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.81, up 11.61% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.81 (up 11.61% YoY), and the FY2025 annual result was 0.8, up 7.8% from the prior year.
• Equity Ratio climbed to 0.81 in Q1 2026 per SLNO's latest filing, from 0.8 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q2 2024 and troughed at 0.14 in Q1 2023.
• A 5-year average of 0.65 and a median of 0.73 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio sank 78.28% in 2023, then surged 528.66% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.39 in 2022, then soared by 123.2% to 0.87 in 2023, then fell by 15.04% to 0.74 in 2024, then advanced by 7.8% to 0.8 in 2025, then gained by 2.08% to 0.81 in 2026.
• Business Quant data shows SLNO's Equity Ratio at 0.81 in Q1 2026, 0.8 in Q4 2025, and 0.82 in Q3 2025.